ES135 is a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids. With its effect to promote neurite outgrowth, ES135 can be applied to the medical use of repairing neuron function. The sequence of ES135 has been patented in Taiwan, EU, China and the United States. A multi-center, double blind, randomized, placebo control study as the pivotal Phase 3 clinical trial for spinal cord injury is on-going.
SM-1 is a 3-in-1 capsule containing 3 commercial drugs with sedative effect. The formulation of SM-1 is designed to make each of the drugs available in a staged sequence with timing of release. Patent applications covering SM-1 were filed worldwide. A Phase 3 clinical trial for SM-1 has been completed in the US.